Drug Treatment for Pathological Gambling

This study has been completed.
National Institute of Mental Health (NIMH)
Information provided by:
University of Iowa
ClinicalTrials.gov Identifier:
First received: February 28, 2003
Last updated: July 25, 2013
Last verified: July 2013
This study will determine whether the drug bupropion is an effective treatment for Pathological Gambling.

Condition Intervention
Drug: Bupropion

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Bupropion Versus Placebo in the Treatment of Pathological Gambling

Resource links provided by NLM:

Further study details as provided by University of Iowa:

Estimated Enrollment: 80
Study Start Date: July 2002
Study Completion Date: April 2006
Primary Completion Date: May 2005 (Final data collection date for primary outcome measure)
Detailed Description:

As gambling opportunities proliferate, PG has become a major health concern. Despite its importance, few treatment options with proven efficacy exist. This study will attempt to identify an effective treatment for PG.

Participants are randomly assigned to receive either bupropion or placebo for 12 weeks. Participants are assessed at baseline and at Weeks 2, 3, 4, 5, 6, 8, 10, and 12. Self administered questionnaires and interviews are used to assess participants. Follow-up assessments are made 1, 3, and 6 months after study completion.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • PG for at least 1 year
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00055393

United States, Iowa
Roy J. and Lucille A. Carver College of Medicine, University of Iowa
Iowa City, Iowa, United States, 52242
Sponsors and Collaborators
University of Iowa
National Institute of Mental Health (NIMH)
  More Information

ClinicalTrials.gov Identifier: NCT00055393     History of Changes
Other Study ID Numbers: R21MH063289  DSIR AT-AS 
Study First Received: February 28, 2003
Last Updated: July 25, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Impulse Control Disorders
Mental Disorders
Antidepressive Agents
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Dopamine Agents
Dopamine Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on May 03, 2016